Washington Watch >
FDA General
FDA Advisers Turn Down New RSV Drug
WASHINGTON -- An FDA advisory committee recommended Wednesday that the agency not approve the investigational drug motavizumab to treat respiratory infections, deciding that it didn't offer any advantages over the drug already on the market, and that it may be more dangerous.
Jun 03, 2010